Study designs: all MPD measure sets of study design type ctrldoses

ctrldoses = control group as well as two or more dosage groups

Select table page: First Prev Next Last
   FILTER RESULTS BY:
Data set Clear All
Procedure / Protocol Clear All
Drug or Challenge Clear All
Panel Clear All
Sex Clear All
Data set MPD ID Procedure / Protocol Drug or Challenge Phenotype Measure Panel No. of Strains Sex Age Sample Size (Avg) Year
    Crabbe1 15403 balance beam ethanol missteps crossing 12.7mm wide balance beam   [n]     12.7mm beam:    control    i.p. doses g/kg:    1.0    1.2    1.4 inbred 7 both 8-16wks N=4 2003
    Crabbe1 15404 balance beam ethanol missteps crossing 15.8mm wide balance beam   [n]     15.8mm beam:    control    i.p. doses g/kg:    1.0    1.2    1.4 inbred 8 both 8-16wks N=5 2003
    Crabbe1 15405 balance beam ethanol missteps crossing 19.0 mm wide balance beam   [n]     19.0mm beam:    control    i.p. doses g/kg:    1.0    1.2    1.4 inbred 8 both 8-16wks N=4 2003
    Crabbe1 15406 grid test ethanol grid habituation, distance traveled   [cm]     control    i.p. doses g/kg:    1.5    2.0    2.5 inbred 8 both 8-16wks N=5 2003
    Crabbe1 15407 grid test ethanol grid habituation, missteps per cm   [n/cm]     control    i.p. doses g/kg:    1.5    2.0    2.5 inbred 8 both 8-16wks N=5 2003
    Gould1 37401 forced swim test lithium duration of immobility   [s]     lithium dose [mg/kg]:    0(saline)    200    300    400 inbred 11 m 7-8wks N=8 2011
    Gould1 37405 drug and metabolite quantification lithium serum lithium concentration   [mmol/L]     lithium dose [mg/kg]:    200    300    400 inbred 11 m 7-8wks N=8 2011
    Gould1 37408 drug and metabolite quantification lithium brain lithium concentration   [mmol/L]     lithium dose [mg/kg]:    200    300    400 inbred 11 m 7-8wks N=8 2011
    Gould2 47131 fear conditioning test nicotine acute group, percent immobility in training chamber after first stimulus pairing   [%]     control    nicotine dose (mg):    0.045    0.09    0.18 inbred 8 m 8-12wks N=11 2011
    Gould2 47136 fear conditioning test nicotine acute group, percent immobility in training chamber, 24h after fear conditioning   [%]     control    nicotine dose (mg):    0.045    0.09    0.18 inbred 8 m 8-12wks N=11 2011
    Gould2 47141 fear conditioning test nicotine acute group, percent immobility in altered context chamber, pre-cue   [%]     control    nicotine dose (mg):    0.045    0.09    0.18 inbred 8 m 8-12wks N=11 2011
    Gould2 47146 fear conditioning test nicotine acute group, percent immobility in altered context chamber, cue   [%]     control    nicotine dose (mg):    0.045    0.09    0.18 inbred 8 m 8-12wks N=11 2011
    Gould3 47301 behavior observation nicotine withdrawal study group, number of grooming episodes (20 min test)   [n]     control    nicotine dose (mg)    3    6.3    12 inbred 8 m 8-12wks N=11 2011
    Gould3 47306 behavior observation nicotine withdrawal study group, number of scratching episodes (20 min test)   [n]     control    nicotine dose (mg)    3    6.3    12 inbred 8 m 8-12wks N=11 2011
    Gould3 47311 behavior observation nicotine withdrawal study group, number of jumping episodes (20 min test)   [n]     control    nicotine dose (mg)    3    6.3    12 inbred 8 m 8-12wks N=11 2011
    Gould3 47321 elevated plus maze nicotine withdrawal study group, percent time in closed arms   [%]     control    nicotine dose (mg)    3    6.3    12 inbred 8 m 8-12wks N=10 2011
    Gould3 47326 elevated plus maze nicotine withdrawal study group, percent time in open arms   [%]     control    nicotine dose (mg)    3    6.3    12 inbred 8 m 8-12wks N=10 2011
    Gould3 47331 elevated plus maze nicotine withdrawal study group, percent time in center   [%]     control    nicotine dose (mg)    3    6.3    12 inbred 8 m 8-12wks N=10 2011
    Gould3 47341 fear conditioning test nicotine withdrawal study group, percent immobility in training chamber after first stimulus pairing   [%]     control    nicotine dose (mg)    3    6.3    12 inbred 8 m 8-12wks N=12 2011
    Gould3 47346 fear conditioning test nicotine withdrawal study group, percent immobility in training chamber, 24h after fear conditioning   [%]     control    nicotine dose (mg)    3    6.3    12 inbred 8 m 8-12wks N=12 2011
    Gould3 47361 fear conditioning test nicotine withdrawal study group, percent immobility in altered context chamber, pre-cue   [%]     control    nicotine dose (mg)    3    6.3    12 inbred 8 m 8-12wks N=12 2011
    Gould3 47366 fear conditioning test nicotine withdrawal study group, percent immobility in altered context chamber, cue   [%]     control    nicotine dose (mg)    3    6.3    12 inbred 8 m 8-12wks N=12 2011
    Koide2 35802 nociception assay (none) capsaicin solution consumption, percent of baseline   [%]     concentration (µM):    0.5    1    4    7    10    15 wild-derived Mishima 14 both 8-12wks N=10 2003
    Maurer1 33201 tail cuff atenolol, isoproterenol pulse rate   [n/min]     control    atenolol 10mg    isoprot 1mg    isoprot 10mg inbred 23 m 7-13wks N=10 2009
    Maurer1 33205 ECG atenolol, isoproterenol heart rate   [n/min]     control    atenolol 10mg    isoprot 1mg    isoprot 10mg inbred 23 m 7-13wks N=10 2009
    Maurer1 33209 tail cuff atenolol, isoproterenol systolic blood pressure   [mmHg]     control    atenolol 10mg    isoprot 1mg    isoprot 10mg inbred 23 m 7-13wks N=10 2009
    Maurer1 33213 ECG atenolol, isoproterenol amplitude of P-wave   [mV]     control    atenolol 10mg    isoprot 1mg    isoprot 10mg inbred 23 m 7-13wks N=10 2009
    Maurer1 33217 ECG atenolol, isoproterenol amplitude of Q-wave   [mV]     control    atenolol 10mg    isoprot 1mg    isoprot 10mg inbred 23 m 7-13wks N=9 2009
    Maurer1 33221 ECG atenolol, isoproterenol amplitude of R-wave   [mV]     control    atenolol 10mg    isoprot 1mg    isoprot 10mg inbred 23 m 7-13wks N=9 2009
    Maurer1 33225 ECG atenolol, isoproterenol amplitude of S-wave   [mV]     control    atenolol 10mg    isoprot 1mg    isoprot 10mg inbred 23 m 7-13wks N=9 2009
    Maurer1 33229 ECG atenolol, isoproterenol duration P-wave   [ms]     control    atenolol 10mg    isoprot 1mg    isoprot 10mg inbred 23 m 7-13wks N=10 2009
    Maurer1 33233 ECG atenolol, isoproterenol interval PR   [ms]     control    atenolol 10mg    isoprot 1mg    isoprot 10mg inbred 23 m 7-13wks N=10 2009
    Maurer1 33237 ECG atenolol, isoproterenol interval RR   [ms]     control    atenolol 10mg    isoprot 1mg    isoprot 10mg inbred 23 m 7-13wks N=10 2009
    Maurer1 33241 ECG atenolol, isoproterenol interval QRS   [ms]     control    atenolol 10mg    isoprot 1mg    isoprot 10mg inbred 23 m 7-13wks N=10 2009
    Maurer1 33245 ECG atenolol, isoproterenol interval QT   [ms]     control    atenolol 10mg    isoprot 1mg    isoprot 10mg inbred 23 m 7-13wks N=10 2009
    Maurer1 33249 ECG atenolol, isoproterenol interval ST   [ms]     control    atenolol 10mg    isoprot 1mg    isoprot 10mg inbred 23 m 7-13wks N=10 2009
    Maurer1 33253 ECG atenolol, isoproterenol area of P-wave   [ms*mV]     control    atenolol 10mg    isoprot 1mg    isoprot 10mg inbred 23 m 7-13wks N=9 2009
    Maurer1 33257 ECG atenolol, isoproterenol area of QRS   [ms*mV]     control    atenolol 10mg    isoprot 1mg    isoprot 10mg inbred 23 m 7-13wks N=9 2009
    Maurer1 33261 ECG atenolol, isoproterenol area of QTc   [ms*mV]     control    atenolol 10mg    isoprot 1mg    isoprot 10mg inbred 23 m 7-13wks N=10 2009
    Maurer1 33266 body weight atenolol, isoproterenol fold change in body weight over testing period   [ratio]     control    atenolol 10mg    isoprot 1mg    isoprot 10mg inbred 23 m 7-13wks N=10 2009
    Maurer1 33270 organ weights atenolol, isoproterenol heart weight   [mg]     control    atenolol 10mg    isoprot 1mg    isoprot 10mg inbred 23 m 7-13wks N=10 2009
    Maurer1 33274 organ weights atenolol, isoproterenol heart weight normalized to body weight   [mg/g]     control    atenolol 10mg    isoprot 1mg    isoprot 10mg inbred 23 m 7-13wks N=10 2009
    Maurer1 33278 organ weights atenolol, isoproterenol atria weight   [mg]     control    atenolol 10mg    isoprot 1mg    isoprot 10mg inbred 23 m 7-13wks N=10 2009
    Maurer1 33282 organ weights atenolol, isoproterenol atria weight normalized to body weight   [mg/g]     control    atenolol 10mg    isoprot 1mg    isoprot 10mg inbred 23 m 7-13wks N=10 2009
    Maurer1 33286 organ weights atenolol, isoproterenol ventricle (both) weight   [mg]     control    atenolol 10mg    isoprot 1mg    isoprot 10mg inbred 23 m 7-13wks N=10 2009
    Maurer1 33290 organ weights atenolol, isoproterenol ventricle (both) weight normalized to body weight   [mg/g]     control    atenolol 10mg    isoprot 1mg    isoprot 10mg inbred 23 m 7-13wks N=10 2009
    Maurer1 33294 organ weights atenolol, isoproterenol atria weight to ventricle weight ratio   [ratio]     control    atenolol 10mg    isoprot 1mg    isoprot 10mg inbred 23 m 7-13wks N=10 2009
    Threadgill1 19401 organ weights acetaminophen liver weight 24h after treatment   [g]     control    24h post-Rx mg/kg:    100    200    300 inbred w/CC7 37 m 8-17wks N=4 2005
    Threadgill1 19404 histopathology acetaminophen necrosis   [%]     control    post-Rx mg/kg:    100    200    300 inbred w/CC7 37 m 8-17wks N=3 2005
    Threadgill1 19410 metabolic panel acetaminophen aspartate transaminase (serum AST)   [IU/L]     control    post-Rx mg/kg:    100    200    300 inbred w/CC7 37 m 8-17wks N=3 2005
    Threadgill1 19412 metabolic panel acetaminophen blood urea nitrogen (serum BUN)   [mg/dL]     control    post-Rx mg/kg:    100    200    300 inbred w/CC7 36 m 8-17wks N=3 2005
    Wiltshire4 52401 immune cell quantification BEZ235 B cells, percent viability   [%]     dose [µM]:    control    0.046    0.137    1.235    11.1    100 inbred w/CC7 34 m 10wks N=4 2015
    Wiltshire4 52407 immune cell quantification BEZ235 T cells, percent viability   [%]     dose [µM]:    control    0.046    0.137    1.235    11.1    100 inbred w/CC7 34 m 10wks N=4 2015
    Wiltshire4 52413 immune cell quantification BEZ235 monocytes, percent viability   [%]     dose [µM]:    control    0.046    0.137    1.235    11.1    100 inbred w/CC7 34 m 10wks N=4 2015
    Wiltshire4 52421 immune cell quantification doxorubicin B cells, percent viability   [%]     dose [µM]:    control    0.046    0.137    1.235    11.1    100 inbred w/CC7 35 m 10wks N=4 2015
    Wiltshire4 52427 immune cell quantification doxorubicin T cells, percent viability   [%]     dose [µM]:    control    0.046    0.137    1.235    11.1    100 inbred w/CC7 35 m 10wks N=4 2015
    Wiltshire4 52433 immune cell quantification doxorubicin monocytes, percent viability   [%]     dose [µM]:    control    0.046    0.137    1.235    11.1    100 inbred w/CC7 35 m 10wks N=4 2015
    Wiltshire4 52441 immune cell quantification idarubicin B cells, percent viability   [%]     dose [µM]:    control    0.046    0.137    1.235    11.1    100 inbred w/CC7 35 m 10wks N=4 2015
    Wiltshire4 52447 immune cell quantification idarubicin T cells, percent viability   [%]     dose [µM]:    control    0.046    0.137    1.235    11.1    100 inbred w/CC7 35 m 10wks N=4 2015
    Wiltshire4 52453 immune cell quantification idarubicin monocytes, percent viability   [%]     dose [µM]:    control    0.046    0.137    1.235    11.1    100 inbred w/CC7 35 m 10wks N=4 2015
    Wiltshire4 52461 immune cell quantification selumetinib B cells, percent viability   [%]     dose [µM]:    control    0.046    0.137    1.235    11.1    100 inbred w/CC7 34 m 10wks N=4 2015
    Wiltshire4 52467 immune cell quantification selumetinib T cells, percent viability   [%]     dose [µM]:    control    0.046    0.137    1.235    11.1    100 inbred w/CC7 34 m 10wks N=4 2015
    Wiltshire4 52473 immune cell quantification selumetinib monocytes, percent viability   [%]     dose [µM]:    control    0.046    0.137    1.235    11.1    100 inbred w/CC7 34 m 10wks N=4 2015
    All boxes             To see more rows use the paging control at top.